Experimental Toxicology, Bayer Pharma AG, D-42096 Wuppertal, Germany.
Regul Toxicol Pharmacol. 2011 Dec;61(3):351-64. doi: 10.1016/j.yrtph.2011.09.007. Epub 2011 Oct 10.
Polymeric methylenediphenyl diisocyanate (MDI) is a high production volume chemical intermediate consisting of monomeric 4,4'-MDI, its 2,2'- and 2,4'-isomers, and higher oligomeric homologues. The toxicity of pMDI has systematically been investigated in previous regulatory and mechanistic studies. One cornerstone of toxicological risk assessment is to understand the critical Mode of Action (MoA) of inhaled MDI aerosol. This paper compares the no-observed-adverse effect levels (NOAELs) in rats from two published whole-body exposure chronic inhalation bioassays with the lung irritation-based point of departures (PODs) from acute and subacute nose-only inhalation studies. Acute irritation was related to elevated concentrations of protein in bronchoalveolar lavage fluid (short-term studies), whilst the chronic events were characterized by histopathology. In the chronic bioassay the exposure duration was either 6 or 18h/day while in all other studies a 6h/day regimens were applied. The major objective of this paper is to analyze the interrelationship of acute pulmonary irritation and the acute-on-chronic manifestations of pulmonary disease following recurrent chronic inhalation exposure. This included considerations on the most critical metrics of exposure with regard to the acute concentration×exposure duration per day (C×T(day)) and the chronic cumulative dose metrics. In summary, this analysis supports the conclusion that the C×T(day) relative to the acute pulmonary irritation threshold is more decisive for the chronic outcome than the concentration per se or the time-adjusted cumulative dose. For MDI aerosols, the acute threshold C×T(day) was remarkably close to the NOAELs of the chronic inhalation studies, independent on their differing exposure mode and regimens. This evidence is supportive of a simple, direct MoA at the site of initial deposition of aerosol. Accordingly, for chemicals reactive to the endogenous nucleophilic agents contained in the lining fluid of the lung, one unifying essential prerequisite for pulmonary injury appears to be a C×T(day) that exhausts the homeostatic pool of MDI-scavenging agents. In the case that threshold is exceeded, the secondary compensatory chronic response may then cause additional superimposed types of chronic pathologies.
多聚亚甲基苯二异氰酸酯(MDI)是一种高产量的化学中间体,由单体 4,4'-MDI、其 2,2'-和 2,4'-异构体以及更高的齐聚物同系物组成。PMDI 的毒性已在先前的监管和机制研究中得到系统研究。毒理学风险评估的一个基石是了解吸入 MDI 气溶胶的关键作用模式(MoA)。本文比较了两篇已发表的全身暴露慢性吸入生物测定中大鼠的未观察到不良效应水平(NOAEL)与急性和亚急性鼻吸入研究中基于肺部刺激的起点(POD)。急性刺激与支气管肺泡灌洗液中蛋白质浓度升高有关(短期研究),而慢性事件的特征是组织病理学。在慢性生物测定中,暴露时间为每天 6 或 18 小时,而在所有其他研究中,应用了每天 6 小时的方案。本文的主要目的是分析反复慢性吸入暴露后急性肺部刺激和慢性肺部疾病的急性加重之间的相互关系。这包括考虑与急性浓度×每天暴露时间(C×T(天))和慢性累积剂量有关的最关键暴露指标。总之,该分析支持以下结论:相对于急性肺部刺激阈值的 C×T(天)对于慢性结果比浓度本身或时间调整的累积剂量更具决定性。对于 MDI 气溶胶,急性阈值 C×T(天)与慢性吸入研究的 NOAEL 非常接近,而与它们不同的暴露模式和方案无关。这一证据支持了一种简单、直接的 MoA,即在气溶胶最初沉积部位。因此,对于与肺衬液中内源性亲核试剂反应的化学物质,肺损伤的一个统一基本前提似乎是耗尽 MDI 清除剂的动态平衡池的 C×T(天)。如果超过阈值,则继发性代偿性慢性反应可能会导致额外的叠加型慢性病理类型。